Pfizer led the pack with fines for five drugs, while the other companies had one to two products.
One of the provisions of the Inflation Reduction Act, which was passed in August and hit pharma lobby groups hard, allows the federal government to hand drugmakers tax penalties if prices for their prescription drugs in Medicare Part D outpace the rate of inflation.
The drugs outlined by the White House may have lower coinsurances for Part D beneficiaries from April 1 to June 30, HHS said, with savings between $2 and $390 per dose.
Here are the 27 products and their drugmakers:
1. Abelcet (Leadiant Biosciences)
2. Akynzeo (Helsinn Therapeutics)
3. Atgam (Pfizer)
4. Aveed (Endo Pharmaceuticals)
5. Bicillin C-R (Pfizer)
6. Bicillin L-A (Pfizer)
7. Carnitor (Leadiant Biosciences)
8. Cytogam (Saol Therapeutics)
9. Elzonris (Stemline Therapeutics)
10. Fetroja (Shionogi & Co.)
11. Flebogamma DIF (Grifols)
12. Folotyn (Allos Therapeutics)
13. Fragmin (Pfizer)
14. Humira (AbbVie)
15. Leukine (Partner Therapeutics)
16. Minocin (Hovione)
17. Mircera (Roche)
18. Nipent (Pfizer)
19. Padcev (Agensys and Seagen)
20. Rybrevant (Johnson & Johnson)
21. Signifor LAR (Recordati)
22. Sylvant (EUSA Pharma)
23. Tecartus (Kite Pharma)
24. Winrho SDF (Cangene)
25. Xiaflex (Endo International)
26. Xipere (Clearside Biomedical)
27. Yescarta (Kite Pharma)
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.